Fetal exposures to many drugs of abuse, e.g., opioids and alcohol (EtOH), are associated with adverse neurodevelopmental problems in early childhood, including abnormalities in activity of the serotonin (5HT) transporter (SERT), which transports 5HT across the placenta. Little is known about the effects of these drugs on SERT expression. Pregnant women who used EtOH or opioids were compared to gestational age-matched controls using a structured questionnaire to determine prenatal substance exposure. Following elective pregnancy termination, placental membranous vesicles and exosomes were prepared from first and second trimester human placentas. Changes in EtOH- or opioid-exposed placental SERT expression and modifications were assessed by quantitative western blot. Novel SERT isoforms were sequenced and analyzed. Opioid-exposed but not EtOH-exposed maternal placentas showed SERT cleavage and formation of new SERT fragments (isoforms). Alcohol-exposed cases showed reduced SERT levels. Antibodies to the N-terminal SERT region did not recognize either of the two cleavage products, while antibodies to the central and C-terminal regions recognized both bands. The secondary band seen in the opioid group may represent a hypophosphorylated SERT fragment. These changes in SERT modifications and expression may result in altered fetal brain serotonergic neurotransmission, which could have neurodevelopmental implications.

The close of one year and the beginning of the next has traditionally been associated with reflections and resolutions. For scholarly journals such as Pharmacotherapy, this is a fitting time to review the objective, big-picture perspective of biomedical publishing. The year 2022 will be remembered for its turbulence in national politics, international affairs, economic unpredictability, and inflation. Wars have begun or continued, and threats for the use of nuclear weapons have heightened to a level not seen in the lifetime of much of the world's population. An all-inclusive list of negative reflections would be much longer. The past year has included many positive events. A focus on scientific progress would include the successful initiation of programs for manned space exploration, deployment of new instrumentation including the James Webb Space Telescope for discovery in the distant universe, and an increasing commitment to slow climate change. Automobile manufacturers announced plans to produce more electric vehicles, and recently, a demonstration of nuclear fusion foreshadows momentous developments in the next few decades in the availability of innovative sources of clean energy. In medical science, 2022 will be remembered for further innovations in the development of mRNA vaccines, the availability of new pharmacotherapy for a reduction in LDL cholesterol, promising treatments for Type 2 diabetes, and revolutionary approaches to the treatment of resistant depression. Artificial intelligence has matured and been applied for the early prediction and diagnosis of sepsis. Across almost all therapeutic areas, advances have occurred that give hope for improving health and quality of life. The need for effectively communicating scientific achievement to the public has become increasingly pronounced. A lack of understanding of scientific findings has produced skepticism in many individuals that fuels mistrust leading a few to embrace conspiracy theories. The response to improve the acceptance of valid scientific investigations and findings needs to involve all parties invested in scientific discovery and dissemination. Biomedical publishing plays a key role in this effort. The biomedical publishing industry is in a dynamic period of change. Scientific journals have been published since the 1600s, and the most durable model of dissemination has involved libraries and individuals paying subscription fees to have access to journal content. This arrangement is being replaced by business models with authors, their funders, or institutions underwriting the costs of publication. Various arrangements are being pursued to produce free and perpetual access to published articles. European and American funding agencies have been some of the primary motivators to make publicly funded research freely available to all readers. The White House Office of Science and Technology Policy issued guidance in 2022 to make the results of taxpayer-supported research freely available by the end of 2025. A hoped-for result of more open-access publishing should be a better appreciation by the public of the value of research. This outcome requires a foundation built on faith that published science is reliable and valid. Achieving this outcome has several pitfalls. The rise of predatory journals with a motive for grift has victimized numerous authors and damaged the scientific record. Manipulation of the peer review process with illegitimate reviewers continues to be exposed and has led to many article retractions. Avoiding plagiarism, image manipulation, and data falsification are additional issues that face credible scientific journals. Pharmacotherapy is committed to publishing content that is valid and impactful. Optimism in addressing the issues driving change in biomedical publishing is the prevailing attitude in the virtual offices of the editorial team. The editorial process is buoyed by methods in place to detect various forms of scientific misconduct. Especially important are the journal's editorial board and a base of peer reviewers who are knowledgeable and insightful. The editorial team is resolved to maintain the integrity of the scientific record created by the journal. The success of these efforts has contributed to Pharmacotherapy's increasing number of annual full-text downloads and a rising impact factor. What can be expected of biomedical publishing in 2023? The momentum toward more journal content that is freely available will continue. Publishers are seeking what has become known as transformative agreements with multi-institutional representation to facilitate manuscript submission by member authors. An increasing focus on providing services to authors will remove cumbersome aspects of the manuscript submission process and make it easier to format revisions or submit to alternative journals. More visual abstracts will accompany full-text articles to summarize the results of research reports and improve the ability of an international and lay readership to appreciate the publication's value. The period between manuscript submission and the availability of the results of peer review will continue to shorten. We are in a period of experimentation in publishing models that has the goal of supporting submissions for authors, providing assurances of the validity of published results, making scientific research understandable and available to the public, and still covering the costs of publication. In the not-too-distant past, professional societies, authors, and publishers debated whether digital publication of journals would prevail over print editions. This has proven to be an unfounded concern. Biomedical publishing is in an analogous period to define new approaches to make scientific discoveries and scholarship more widely available for societal benefits. The authors have declared no conflicts of interest for this article.

The author has declared no conflicts of interest.

The authors have no conflict of interest to declare.

Patient and providers’ fear of fetal exposure to medications may lead to discontinuation of treatment, disease relapse, and maternal morbidity. Placental drug transporters play a critical role in fetal exposure through active transport but the majority of data are limited to the 3rd trimester, when the majority of organogenesis has already occurred. Our objective was to define gestational age (GA) dependent changes in protein activity, expression and modifications of five major placental drug transporters: SERT, P-gp, NET, BCRP and MRP3. Apical brush border membrane fractions were prepared from fresh 1st, 2nd and 3rd trimester human placentas collected following elective pregnancy termination or planned cesarean delivery. A structured maternal questionnaire was used to identify maternal drug use and exclude exposed subjects. Changes in placental transporter activity and expression relative to housekeeping proteins were quantified. There was evidence for strong developmental regulation of SERT, NET, P-gp, BCRP and MRP3. P-gp and BCRP decreased with gestation (r = −0.72, p < 0.001 and r = −0.77, p < 0.001, respectively). Total SERT increased with gestation but this increase was due to a decrease in SERT cleavage products across trimesters. Uncleaved SERT increased with GA (r = 0.89, p < 0.001) while cleaved SERT decreased with GA (r = −0.94, p < 0.001). Apical membrane NET overall did not appear to be developmentally regulated (r = −0.08, p = 0.53). Two forms of MRP3 were identified; the 50 kD form did not change across GA; the 160 kD form was steady in the 1st and 2nd trimester and increased in the 3rd trimester (r = 0.24, p = 0.02). The 50 kD form was expressed at higher levels. The observed patterns of SERT, NET P-gp, BCRP and MRP3 expression and activity may be associated with transporter activity or decreased placental permeability in the 1st trimester to transporter specific substrates including commonly used psychoactive medications such as anti-depressants, anti-psychotics, and amphetamines, while transport of nutrients and serotonin is important in the 1st trimester. Overall these observations are consistent with a strong protective effect during organogenesis. 3rd trimester estimates of fetal exposure obtained from cord blood likely significantly overestimate early fetal exposure to these medications at any fixed maternal dose.

Archaeological evidence establishes cannabis as one of humanity’s oldest cultivated plants. Various authorities estimate that the history of its use began 5–10,000 years ago, initially in Asia, where the plant is indigenous and spreading eventually worldwide. Commonly referred to in some countries as marijuana, the more universal nomenclature is “cannabis,” the genus name adopted from the main botanical sources of Cannabis sativa and Cannabis indica, and the less common Cannabis ruderalis. Similar to many botanical substances, cannabis contains hundreds of chemical constituents; thus, it possesses a rich pharmacologic profile, one that remains to be fully characterized and is subject to considerable speculation regarding its overall value and liability for human use. Cannabis use continues to grow in the United States as reflected by an increasing number of states that have legalized either medical or recreational marijuana use (or both), decriminalized possession, or introduced regulations for controlled cultivation in a rapidly expanding commodity market. The thriving marijuana industry is currently credited with adding thousands of new jobs to the United States economy. The expansion of marijuana availability and use is an economic driver for development of marijuana-related formulations and products. A previous editorial in Pharmacotherapy summarized points of view about the increasing interest in marijuana use and development of compounds with structural similarity to its principal constituents, the cannabinoids.1 The journal has since published several reviews that discuss various aspects of the pharmacology of the cannabinoids and issues related to their use in pharmacotherapy. These articles are grouped together in a virtual issue of the journal (Pharmacotherapy Publications Related to Marijuana/Cannabinoids). They are relevant in maintaining current knowledge of the potential benefits and liabilities of cannabis and related compounds. The literature supporting the use of cannabis for pain and muscle spasms is a prominent reason for recommending its use in pharmacotherapy. Borgelt et al provide a comprehensive review through 2013 for evidence-based support of the use of medical cannabis.2 A subsequent review in 2018 by Bowen and McRae-Clark focused on the evidence for the benefit of smoked cannabis in randomized placebo-controlled studies.3 Strict criteria of scientific rigor for inclusion in the data analysis resulted in finding sparse evidence to conclude that smoked cannabis would increase the quality of life in patients with some conditions that have been promoted for its therapeutic value. Rhyne et al.4 found patient-reported effects to be highly significant for the reduction of migraine headaches with medical marijuana. For painful states with a significant peripheral pathophysiology, cannabinoid compounds with limited central nervous system availability might have therapeutic advantages. Two reviews by Romero-Sandoval et al.5, 6 provide in-depth discussion on issues of cannabinoid use for painful conditions. The chemical complexity of cannabis has stimulated research to characterize the contribution of its individual components to its overall pharmacologic effects. Delta-9-tetrahydrocannabinol (THC) has long been recognized as the principal constituent producing psychoactive or euphoric effects. Cannabidiol (CBD), along with various related chemicals and formulations, have been targeted as compounds with possible therapeutic value without euphoric effects. These possibilities are explored in a review of CBD preparations as therapeutic agents by Fasinu et al.7 With the increasing legalization of recreational marijuana, a perception among many individuals may exist that negative consequences are lacking. As noted by several authors in the virtual issue, multiple negative consequences can accompany regular cannabis use, especially when begun in early adolescence. One consequence of heavy use is the development of cannabis use disorder (CUD) with an insidious onset. A review of the clinical trial database for treatment of CUD is provided by Sherman and McRae-Clark,8 as well as the scientific outlook for development of treatments to ameliorate its effects. Another adverse consequence that appears to be increasing emergency department visits is the cannabinoid hyperemesis syndrome. This condition is characterized by paroxysmal episodes of nausea and vomiting that in a severe form can lead to dehydration and renal failure. Richards et al.9 provide a systematic review of the literature of this condition. The illicit market for cannabis has existed for many decades and is not likely to diminish quickly with easing of restrictions for legalization of marijuana possession and use. A response of illicit marketers to legal competition is the development and/or promotion of cannabinoid-based preparations, botanicals with psychoactive properties, and newer designer drugs. The proliferation of many of these substances outpaces federal and state legislation to regulate their availability. Rech et al.10 provide a detailed profile of prominent examples of new drugs of abuse. Finally, Armstrong et al.11 document major toxicity in a case series characterized by multiple organ failure associated with synthetic cannabinoid use. The virtual issue of Pharmacotherapy collates articles published in the journal over the past few years with a common theme of increasing the understanding of the value of cannabis and related compounds in pharmacotherapy. The articles present two aspects of the use of cannabinoid compounds. First, botanical cannabis for a variety of medicinal purposes has gained increasing acceptance, but evidence-based support is conjecture for many indications. Second, caution continues to be warranted among health care professionals with recognition of the CUD, a hyperemesis syndrome, and special liability for long-term cognitive problems when recreational use begins during development. The landscape of legalization of cannabis is rapidly evolving. Taken together, the reviews in the virtual issue provide a foundation of knowledge on several pertinent issues related to the use and development of cannabinoid compounds.

Pharmacotherapy: The Journal of Human Pharmacology and Drug TherapyVolume 40, Issue 5 p. 376-378 Editorial The Role of Scientific Publishing in the SARS-CoV-2 Pandemic C. Lindsay DeVane, Corresponding Author C. Lindsay DeVane Editor-in-Chief [email protected] orcid.org/0000-0003-1608-9911 Medical University of South Carolina, Charleston, South Carolina, USASearch for more papers by this author C. Lindsay DeVane, Corresponding Author C. Lindsay DeVane Editor-in-Chief [email protected] orcid.org/0000-0003-1608-9911 Medical University of South Carolina, Charleston, South Carolina, USASearch for more papers by this author First published: 04 May 2020 https://doi.org/10.1002/phar.2402Citations: 1 Conflict of interest: The authors have declared no conflicts of interest for this article. The opinions expressed in this editorial are those of the author and do not necessarily represent the position of Pharmacotherapy or the American College of Clinical Pharmacy. Invited editorials are not peer reviewed. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Dean KR, Krauer F, Walloe L, et al. Human ectoparasites and the spread of plague in Europe during the Second Pandemic. PNAS 2018; 115(6): 1304–130. 10.1073/pnas.1715640115 CASPubMedWeb of Science®Google Scholar 2Gage KL, Kosoy MY. Natural history of plague: perspectives from more than a century of research. Annu Rev Entomol 2005; 50: 505–28. 10.1146/annurev.ento.50.071803.130337 CASPubMedWeb of Science®Google Scholar 3Martini M, Gazzaniga V, Bragazzi NL, Barberis I. The Spanish influenza pandemic: a lesson from history 100 years after 1918. J Prev Med Hyg 2019; 60: E64–7. CASPubMedGoogle Scholar 4Lodise T, Rybak M. COVID-19: important therapy considerations and approaches in this hour of need. Pharmacotherapy 2020; 40(5): 379–81. https://doi.org/10.1002/phar.2396 10.1002/phar.2396 CASPubMedWeb of Science®Google Scholar 5Stringer KA, Puskarich MA, Kenes MT, Dickson RP. COVID- 19: the uninvited guest in the intensive care unit (ICU): implications for pharmacotherapy. Pharmacotherapy 2020; 40(5): 382–6. https://doi.org/10.1002/phar.2394 10.1002/phar.2394 CASPubMedWeb of Science®Google Scholar 6Bauman JL, Tisdale JE. Chloroquine and hydroxychloroquine in the era os SARSCoV2: caution on their cardiac toxicity. Pharmacotherapy 2020; 40(5): 387–8. https://doi.org/10.1002/phar.2387 10.1002/phar.2387 CASPubMedWeb of Science®Google Scholar 7Barlow A, Landolf K, Barlow B, Heavner J, Claassen C, Heavner M. Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019. Pharmacotherapy 2020: 40(5): 416–37. https://doi.org/10.1002/phar.2398 10.1002/phar.2398 CASPubMedWeb of Science®Google Scholar 8Dashti-Khavidaki S, Khalili H. Considerations for statin therapy in patients with COVID-19. Pharmacotherapy 2020; 40(5): 484–6. https://doi.org/10.1002/phar.2397 10.1002/phar.2397 CASPubMedWeb of Science®Google Scholar 9Sodhi M, Etminan M. Therapeutic potential for tetracyclines in the treatment of COVID-19. Pharmacotherapy 2020; 40(5): 487–8. https://doi.org/10.1002/phar.2395 10.1002/phar.2395 CASPubMedWeb of Science®Google Scholar Citing Literature Volume40, Issue5May 2020Pages 376-378 ReferencesRelatedInformation

Archaeological evidence establishes cannabis as one of humanity's oldest cultivated plants. Various authorities estimate that the history of its use began 5-10,000 years ago, initially in Asia, where the plant is indigenous and spreading eventually worldwide. Commonly referred to in some countries as marijuana, the more universal nomenclature is "cannabis," the genus name adopted from the main botanical sources of Cannabis sativa and Cannabis indica, and the less common Cannabis ruderalis.

Pharmacotherapy: The Journal of Human Pharmacology and Drug TherapyVolume 39, Issue 1 p. 4-6 Editorials Pharmacotherapy Rounds: When Old Drugs Require New Guidelines C. Lindsay DeVane, C. Lindsay DeVane Editor-in-Chief devaneL@musc.edu Search for more papers by this author C. Lindsay DeVane, C. Lindsay DeVane Editor-in-Chief devaneL@musc.edu Search for more papers by this author First published: 13 January 2019 https://doi.org/10.1002/phar.2206Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume39, Issue1January 2019Pages 4-6 RelatedInformation

Pharmacotherapy: The Journal of Human Pharmacology and Drug TherapyVolume 39, Issue 6 p. 624-625 Editorial Pharmacologic Issues in Treating Neurodevelopmental Disorders C. Lindsay DeVane, Corresponding Author C. Lindsay DeVane devaneL@musc.edu orcid.org/0000-0003-1608-9911 Search for more papers by this author C. Lindsay DeVane, Corresponding Author C. Lindsay DeVane devaneL@musc.edu orcid.org/0000-0003-1608-9911 Search for more papers by this author First published: 21 May 2019 https://doi.org/10.1002/phar.2277 Conflict of interest: The authors have declared no conflicts of interest for this article. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume39, Issue6June 2019Pages 624-625 RelatedInformation

Pharmacotherapy: The Journal of Human Pharmacology and Drug TherapyVolume 39, Issue 10 p. 968-969 Editorial On the 40th Anniversary of the American College of Clinical Pharmacy: Musing About Books, Journals, and Libraries C. Lindsay DeVane, Corresponding Author C. Lindsay DeVane Editor-in-Chief devaneL@musc.edu orcid.org/0000-0003-1608-9911 Search for more papers by this author C. Lindsay DeVane, Corresponding Author C. Lindsay DeVane Editor-in-Chief devaneL@musc.edu orcid.org/0000-0003-1608-9911 Search for more papers by this author First published: 13 October 2019 https://doi.org/10.1002/phar.2327 Conflict of interest: The authors have declared no conflicts of interest for this article. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume39, Issue10October 2019Pages 968-969 RelatedInformation

The objective of this trial, Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART), was to provide support and guidance for an evidence-based approach for the selection and monitoring of initial pharmacotherapy in patients with autism by assessing predictors of efficacy, tolerability, and safety. This randomized double-blind parallel-group study was conducted in three academic medical centers and a single private pediatric practice. Eighty children or adolescents (aged 6-17 yrs) with autistic disorder were enrolled, and 61 patients were randomized to the study drug. Of those patients, 51 completed the 10-week trial, and 31 completed an optional 12-week blinded extension phase. All patients were treated with 2 weeks of placebo before random assignment to receive aripiprazole (31 patients) or risperidone (30 patients) for 10 weeks. Sixteen placebo responders (20%) were excluded from further analysis. Drug dosing followed U.S. Food and Drug Administration (FDA) labeling, and weekly dosage adjustments were allowed until week 4; patients were then maintained on a fixed dose for 6 additional weeks. Safety, physical, and psychological assessments were recorded weekly or every 2 weeks. No significant differences in severity of illness between the aripiprazole and risperidone groups were noted at baseline. All patients significantly improved on the Aberrant Behavior Checklist-Irritability subscale after 1 week and continued for the remaining 9 weeks and the extension phase. Improvement was greatest in the risperidone group at every assessment period and was statistically significantly better than that in the aripiprazole group at weeks 3 and 6 (p<0.05). No dose-limiting adverse events occurred during the dose-titration period. Mean weight gain in the aripiprazole group was significantly less than that in the risperidone group at week 4 (0.62 vs 1.38 kg, p=0.033) and week 10 (1.61 vs 3.31 kg, p<0.001), but the difference became nonsignificant for the 31 patients completing the 3-month extension phase (4.36 vs 5.55 kg, p=0.26). Pharmacotherapy of patients with autism spectrum disorder resulted in behavioral improvement within 1 week and lasted at least 22 weeks. Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial. Our trial supports previous results of drug efficacy and safety in patients with autism spectrum disorder from other trials and extends the evidence-based support for choosing an FDA-approved drug for initial pharmacotherapy for autism spectrum disorder.

Pharmacotherapy: The Journal of Human Pharmacology and Drug TherapyVolume 38, Issue 3 p. 306-308 Editorial Pharmacotherapy Rounds: Can We Improve the Fate of Unused Drugs? C. Lindsay DeVane, C. Lindsay DeVane Editor-in-Chief devaneL@musc.edu Search for more papers by this author C. Lindsay DeVane, C. Lindsay DeVane Editor-in-Chief devaneL@musc.edu Search for more papers by this author First published: 25 March 2018 https://doi.org/10.1002/phar.2098Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume38, Issue3March 2018Pages 306-308 RelatedInformation

Pharmacotherapy: The Journal of Human Pharmacology and Drug TherapyVolume 38, Issue 6 p. 586-587 Editorial Anticoagulation Research and Awareness—A Cross-Therapeutic Need C. Lindsay DeVane, C. Lindsay DeVane Editor-in-Chief devaneL@musc.edu Search for more papers by this author C. Lindsay DeVane, C. Lindsay DeVane Editor-in-Chief devaneL@musc.edu Search for more papers by this author First published: 21 June 2018 https://doi.org/10.1002/phar.2123Citations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article.Citing Literature Volume38, Issue6June 2018Pages 586-587 RelatedInformation

Pharmacotherapy: The Journal of Human Pharmacology and Drug TherapyVolume 38, Issue 1 p. 4-5 Editorial A Watershed Outlook for Pharmacotherapy in 2018 Lindsay DeVane, Lindsay DeVane Editor-in-Chief devanel@musc.edu Search for more papers by this author Lindsay DeVane, Lindsay DeVane Editor-in-Chief devanel@musc.edu Search for more papers by this author First published: 12 January 2018 https://doi.org/10.1002/phar.2072Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume38, Issue1January 2018Pages 4-5 RelatedInformation

Pharmacotherapy: The Journal of Human Pharmacology and Drug TherapyVolume 37, Issue 7 p. 779-780 Editorial Opioid Use and Abuse and Neonatal Abstinence Syndrome C. Lindsay DeVane, C. Lindsay DeVane Editor-in-Chief devanel@musc.edu Search for more papers by this author C. Lindsay DeVane, C. Lindsay DeVane Editor-in-Chief devanel@musc.edu Search for more papers by this author First published: 19 July 2017 https://doi.org/10.1002/phar.1969Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume37, Issue7THEMED ISSUE ON OPIOID ABUSE AND NEONATAL ABSTINENCE SYNDROMEJuly 2017Pages 779-780 RelatedInformation

Pharmacotherapy: The Journal of Human Pharmacology and Drug TherapyVolume 36, Issue 9 p. 953-954 Pharmacotherapy Rounds Women's Pharmacotherapy Matters C. Lindsay DeVane, C. Lindsay DeVane Editor-in-Chief devanel@musc.edu Search for more papers by this author C. Lindsay DeVane, C. Lindsay DeVane Editor-in-Chief devanel@musc.edu Search for more papers by this author First published: 21 September 2016 https://doi.org/10.1002/phar.1809Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume36, Issue9September 2016Pages 953-954 RelatedInformation